Company: IXHL
Filing Date: 2025-03-24
Form Type: S-3
Source: 0001013762-25-001587
Chunk: 17

Company: Incannex Healthcare Inc.
Filing Date: 2025-03-24
Form: S-3
Chunk 17
---
 cash. Such proceeds will be
used for working capital and general corporate purposes.

The selling stockholders will
pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal
services or any other expenses incurred by the selling stockholders in disposing of these Shares. We will bear all other costs, fees and
expenses incurred in effecting the registration of the Shares covered by this prospectus, including, without limitation, all registration
and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our accountants.

<div align='center'>9

SELLING STOCKHOLDERS</div>

This prospectus covers the
resale from time to time of up to an aggregate of 65,971,805 Shares by the selling stockholders, consisting of (i) 9,687,045 shares of
Common Stock, (ii) 1,887,045 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to purchase shares of Common
Stock, and (iii) 54,797,715 shares of Common Stock issuable upon the exercise of the Series A Warrants to purchase shares of Common Stock.
The Shares registered for resale herein are pursuant to the Securities Purchase Agreements between us and the selling stockholders and
relate to shares held by the selling stockholders not otherwise previously registered for resale.

The selling stockholders may
offer and sell, from time to time, any or the Shares described under the column “Number of Shares of Shares Being Offered”
in the table below. Except for the ownership of the securities, the selling stockholders have not had any material relationship with us
within the past three years.

As used in this prospectus,
the term “selling stockholders” includes the selling stockholders listed in the table below, together with any additional
selling stockholders listed in a subsequent amendment to this prospectus, and their donees, pledgees, assignees, transferees, distributees
and successors-in-interest that receive shares in any non-sale transfer after the date of this prospectus.

The table below lists
the selling stockholders and other information regarding the beneficial ownership of the Shares by each of the selling stockholders
as of March 12, 2025. The following table also provides the number of Shares that may be sold by each selling stockholder under this
prospectus and that each selling stockholder will beneficially own assuming all the Shares that may be offered pursuant